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SAMMANFATTNING 
 
Mastcellstryptas är ett trypsinliknande proteas som lagras i komplex med 
heparinproteoglykan eller kondroitinsulfatproteoglykan i mastcellens granula. 
Tryptas är en viktig inflammationsmediator vid bland annat allergiska reaktioner 
och astma. I denna studie har vi undersökt förutsättningarna för aktivering av 
humant βI-tryptas och βII-tryptas, vilka är de dominerande typerna av tryptas i 
humana mastceller. βI-tryptas och βII-tryptas skiljer sig åt strukturellt med endast 
en aminosyra, nummer 102, där βI-tryptas har asparagin (Asn) som tillika är en 
glykosyleringsplats och βII-tryptas har lysin (Lys). Detta betyder att βI-tryptas är 
glykosylerat medan βII-tryptas saknar glykosylering på den positionen. Vi har 
visat att både βI-tryptas och βII-tryptas är beroende av heparin för aktivering och 
att optimal aktivitetsnivå uppnåddes vid surt pH för βI-tryptas medan βII-tryptas 
inte är lika pH-beroende. Både βI-tryptas och βII-tryptas har stark affinitet för 
heparin-Sepharose vid surt pH, denna affinitet minskar vid neutralt pH. βI-tryptas 
och βII-tryptas visade båda en klockformad dos-responskurva för heparin-
inducerad aktivering. Resultaten från denna studie visar, sammantaget med 
resultat från en parallell studie, att heparin har en betydande roll för aktivering av 
humant β-tryptas. 
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ABSTRACT 
 
Mast cell tryptase, a tetrameric serine protease stored in mast cell granules in 
complex with heparin proteoglycan or chondroitin sulphate proteoglycan, is an 
important effector molecule in inflammatory reactions like allergies and asthma. 
In this study we have investigated the requirements for activation of human βI-
tryptase and βII-tryptase, the major tryptases of human mast cells. βI-tryptase and 
βII-tryptase differ in only one amino acid, no. 102, where βI-tryptase has an 
asparagine (Asn) residue which is also site for glycosylation while βII-tryptase 
has a lysine (Lys) residue and lacks glycosylation at that site. We found that both 
βI-tryptase and βII-tryptase were dependent on heparin for activation and that 
optimal activity for βI-tryptase occurred at acidic pH while activation of βII-
tryptase was less pH-dependent.  Both βI-tryptase and βII-tryptase had a strong 
affinity for heparin-Sepharose at acidic pH but this affinity decreased at neutral 
pH. The β-tryptases both showed a bell shaped dose response curve for heparin 
induced activity. These results, taken together with results from a parallel study 
indicate an important role for heparin in the activation of human β-tryptase. 
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INTRODUCTION 
 
The immune system protects the body from pathogens for example bacteria, 
viruses and parasites. The immune response is divided into two major groups, the 
innate (non specific) immune response and the adaptive immune response. The 
innate response occurs as a first line of defence when exposed to a pathogen and 
is executed mainly by phagocytic cells such as monocytes, macrophages and 
polymorphonuclear neutrophils. The adaptive immune response is primarily based 
on the actions of lymphocytes, mainly B-cells and T-cells, and is highly specific 
for a particular pathogen.  Several other cell types including basophils, mast cells 
and platelets are also involved in combating infection by mediating inflammation 
in the affected area. The purpose of inflammation is to increase the concentration 
of cells participating in an immune response at the site of the infection. This is 
accomplished by increasing the blood flow to the area, increasing capillary 
permeability to allow for larger molecules than normal to pass from the vessels to 
the surrounding tissue and by facilitating migration of leukocytes into the infected 
area by means of chemotaxis.  
When the immune system fails to function normally different problems can occur. 
Autoimmunity is a result of the immune system failing to recognize the body’s 
own tissue,  interpreting the tissue as foreign and mounts a response towards it. 
This occurs for instance in  rheumatoid arthritis. If parts of the immune system 
fails it may be unable to generate a sufficient response to an infection, this is 
called immunodeficiency and can be hereditary or acquired.  Yet another case is 
when the immune system mounts a reaction that is unproportional to the potential 
harm of the antigen, or a reaction is exerted after exposure to a harmless antigen. 
This is referred to as hypersensitivity and in these cases the immune response 
itself can be more damaging than the antigen the body is exposed to.  Allergic 
reactions are examples of hypersensitivity. Hypersensitivity is divided into four 
different types. A type I reaction is when an allergen cross-links two IgE 
molecules bound to the surface of mast cells causing degranulation and 
subsequent release of inflammatory mediators that produce allergic reactions. 
Type II reaction is an antibody mediated reaction where antibodies of either IgM 
or IgG type are produced to interact with surface antigen on the target cell. The 
target cell can be either the body’s own cells or foreign antigen such as for 
example transfused blood cells. The labelling with antibodies on these cells will 
subsequently lead to destruction of the cells by the immune system. Type III 
reaction is generated when antigen-antibody complexes form at a rate that cannot 
be sufficiently cleared by the body. Accumulation of these immune complexes in 
tissues causes inflammation and tissue damage. Type IV reactions occur as a 
result of specific T cells responding to an antigen, resulting in release of cytokines 
which in turn promotes release of inflammatory mediators from macrophages. 
Examples of type IV reactions are contact allergies (Roitt et al., 2001). 
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Mast cells 
Mast cells (MCs) originate from haematopoietic stem cells in the bone marrow 
and are released to the circulation as immature cells. The MCs mature in different 
tissues under the influence of local growth factors and are, unlike basophils, 
usually not found in the circulation after maturation. MCs are found throughout 
the body, primarily in tissues that come in contact with the outside of the body for 
example mucus membranes in the digestive system and the respiratory tract. MCs 
are important cells in various inflammatory conditions by releasing the contents of 
their secretory granules which promotes inflammation and in combating 
infections caused by extracellular parasites. The contents of the granules include 
several preformed inflammatory mediators such as histamine, cytokines, serglycin 
proteoglycans and proteases of three different classes. The MC proteases are 
tryptases, chymases and carboxypetidase A (CPA). In addition to the preformed 
substances released there is also de novo synthesis of arachidonic acid metabolites 
such as leukotrienes-C4 and prostaglandin-D2 by activated mast cells (Hallgren et 
al 2006, Hallgren et al 2004). Human MCs are divided into two populations, 
mucosal mast cells (MMCs) primarily found in the mucosa of the gastrointestinal 
tract and the airways and connective tissue mast cells (CTMCs) primarily found in 
the skin and serosal cavity. MCs can also be classified according to the contents 
of the granules. MCT contain tryptase while MCTC contain tryptase as well as 
chymase and CPA. Activation of MCs can occur as part of the adaptive immune 
response when an antigen binds to two IgE antibodies that bind to specific 
receptors, FcεRI, on the mast cell surface. The IgE antibodies are produced by 
plasma cells as a response to encountering an antigen such as pollen or a parasite 
and bind with high affinity to the FcεRI. This cross-linking of IgE molecules 
stimulates degranulation with release of preformed inflammatory mediators and 
de novo synthesis of others (see above). MCs can also be activated directly via 
receptors on its cell surface by for instance complement factors such as C5a and 
C3a, different drugs, different pathogens and direct cell-cell interactions with 
activated T cells (Roitt et al 2001).  
 
Tryptase and proteoglycans 
Tryptase is a protease (a proteolytic enzyme) named for its preference to cleave 
substrates in a trypsin-like way at the C-terminal end of the amino acid residues of 
Lysine (Lys) and Arginine (Arg), a specificity also seen in the pancreatic enzyme 
trypsin. Several different tryptases have been found in MCs in different species 
(Hallgren et al 2006). In humans several MC tryptases are known, they include α-, 
β-, γ-, δ- tryptase and transmembrane tryptase (TMT) (Jogie-Brahim et al 2004) 
with β-tryptase being the main form stored in human MCs. β-tryptase is further 
divided into three isoenzymes, βI, βII and βIII. βI and βII differ in only one amino 
acid whereas βIII differ in an additional three amino acids compared to βI/βII. βI 
and βII differ at position 102 where βI has Asn and βII has Lys. Asn 102 is part of 
an N-glycosylation site and βI is glycosylated at this position while β-II is 
unglycosylated (Vanderslice  et al 1990).  
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Tryptase is stored in MC granules in its active form as a tetramer in a complex 
with heparin proteoglycan (heparin PG) or chondroitin sulphate proteoglycan 
(CSPG).  In the tetramer the active sites of the tryptase molecules are facing a 
central pore, a structure that limits the number of substrates that can be cleaved 
due to the size of the substrates. This tetramer structure also makes it difficult for 
tryptase inhibitors to be effective. There are two types of proteoglycans expressed 
by human MCs, heparin PG and CSPG. Heparin is a glycosaminoglycan (GAG) 
consisting of repeating disaccharide units of glucuronic acid or iduronic acid and 
glucosamine. Heparin is negatively charged due to a high number of sulphate 
groups. Heparin PG is made up of a protein core (serglycin) to which the GAGs 
are attached.  It has been shown that heparin PG, or other negatively charged 
polysaccharides, is required to form active tryptase tetramers of mouse mast cell 
protease 6 (mMCP-6) and that formation of tetramers occur at acidic pH (Hallgren 
et al 2000).  Chondroitin sulphate proteoglycan has the same type of protein core 
as heparin PG while the GAGs are made up from repeating disaccharide units of 
glucuronic acid and galactosamine. CSPG is normally not as negatively charged 
as heparin PG.  
The aim of this study has been to investigate the role of heparin in the activation 
and formation of active tetramers of human βI-tryptase and βII-tryptase.  
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MATERIALS AND METHODS 
 
Recombinant βI/ βII-tryptase DNA had previously been ligated into a pCEP Pu2 
vector, transformed into chemo-competent E. coli (MC1061) and after confirming 
the correct DNA sequence transfected into 293-EBNA cells (Hallgren et al 2004). 
Protein expression 
Recombinant β-tryptase was expressed in 293-EBNA cells in serum-free DMEM 
(National Veterinary Institute, Uppsala) supplemented with 2mM L-glutamine 
(National Veterinary Institute, Uppsala), 50µg/ml Gentamycin (National 
Veterinary Institute, Uppsala), 5 µg/ml Puromycin (Sigma, Steinheim, Germany) 
and 10% FCS (Invitrogen, Life Technologies, Groningen, The Netherlands) at 
37ºC and 5% CO2. Puromycin was used for selection of cells containing the pCEP 
Pu2 vector and Gentamycin was used as a general antibiotic.  
Purification of recombinant tryptase 
The recombinant β-tryptase construct contained a histidine-tag (6 x His) and an 
enterokinase (EK) cleavage site (Asp-Asp-Asp-Asp-Lys) between the His-tag and 
the mature β-tryptase sequence. Recombinant tryptase protein was purified from 
conditioned media collected from the transfected 293-EBNA cells. Conditioned 
media was collected and centrifuged at 418 x g for 10 min, the supernatants were 
collected and stored at- 20º C while awaiting purification.  Ni-NTA agarose 0.5 
ml (QIAGEN, GmbH, Hilden, Germany) was loaded on a 10 ml Poly-prep 
Chromatoghraphy column (Bio-Rad, Hercules, USA) and washed with dH2O. 
Thawed media (~750 ml) was applied to the column. The column was then 
washed with 3 x 10ml PBS (pH 7.5) + 0,1% Tween containing 1M-2M NaCl and 
the protein eluted with 100mM Imidazol in PBS pH 7.5. The fractions collected 
were analyzed by SDS-PAGE in a Laemmli system and stained with Coomassie 
Brilliant Blue. Fractions with pure tryptase were pooled and stored at 4ºC. 
Concentration of tryptase was determined by measuring A280 (Lambert Beers law) 
using a calculated molar extinction coefficient of 64 970 M-1 cm-1.  
Enterokinase  cleavage 
To remove the 6 x His-tag and EK cleavage peptide the fusion protein was 
incubated with enterokinase (Roche Molecular Biochemicals, Mannheim, 
Germany) at an EK/fusion protein ratio of 1:500 in PBS pH 6.0 at 37 ºC for 15 
hours.  
Enzymatic assays 
Tryptase activity was measured in 96-well microtiter plates. 250 ng of EK-
digested fusion protein was incubated in PBS with pH ranging from 5.5-7.5,  
either in the presence or absence of heparin and in a total volume of 130-200 µl, 
for 30 min at room temperature. Thereafter 20 µl of S-2288, a chromogenic 
substrate (2mM; H-D-Ile-Pro-Arg-pNA; Chromogenix, Mölndal, Sweden), was 
added and the absorbance at 405 nm was recorded with a spectrophotometer 
(Titertek Multiscan, Flow Laboratories).  In another experiment 250 ng of tryptase 
was incubated in PBS pH 6.0 with heparin in concentrations ranging from 0-
1000µg/250ng tryptase for 30 min at room temperature before addition of S-2288 
and measurement of activity was performed as described previously. Activities 
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were determined as the average of three measurements and the results are given 
with ± standard deviation.  
Heparin-Sepharose chromatography 
Affinity chromatography was performed on a 10 ml Poly-Prep Chromatography 
column containing approximately 0.5 ml heparin-Sepharose (Amersham 
Pharmacia Biotech AB, Uppsala, Sweden). The column was equilibrated with 
PBS pH 6.0 or 7.5. EK-digested β-tryptase, 40 µg in a total volume of 320 µl,  
was incubated for 15 min on the column. The protein was then eluted by washing 
the column with 400 µl of PBS (pH 6.0 or 7.5) with an increasing concentration of 
NaCl (ranging from 0.15M to 2.0M). Samples from each fraction (10 µl) were 
incubated with PBS pH 6.0 (105 µl) and 1 µg heparin (10 µl of 0,1 µg/µl) at room 
temperature for 30 min. Tryptase activity was measured after addition of S-2288 
as described above.  
 
 
RESULTS AND DISCUSSION 
 
Expression of human βI-and βII-tryptase 
 
Human βI-and βII-tryptases were expressed in 293-EBNA cells, a human cell line 
system. Recombinant β-tryptase has previously been expressed in insect cells 
(Huang et al 2001, Wang et al 1998, Sakai et al 1996) or in yeast (Chan et al 
1999, Niles et al 1998) but to our knowledge this is the first report describing 
expression in a human system.  The recombinant fusion proteins were purified on 
Ni-NTA agarose and cleaved by EK-digestion, obtaining the mature forms of βI-
and βII-tryptase monomers (Fig. 1) 
 
Fig. 1Recombinant βI-tryptase and βI-tryptase purified from cell culture medium, digested with 
EK and analyzed on SDS-PAGE.  
The βI-tryptase is showing a larger size and a somewhat fuzzy appearance 
compared to βII-tryptase on SDS-PAGE. This indicates that the βI-tryptase is 
glycosylated at Asn 102. The glycosylation of βI-tryptase is the only major 
difference in the two isoforms since they only differ in one amino acid, 102.  
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Activation of human βI-and βII-tryptase 
 
Human βI-and βII-tryptase fusion proteins were digested with EK at pH ranging 
from 5.5-7.5 and then incubated with or without heparin. After incubation the 
sample was taken to pH7.5 to obtain optimal conditions for substrate cleavage and 
the chromogenic substrate S-2288 was added. The enzymatic activity of the 
tryptase was then measured. In the absence of heparin tryptase activity was low or 
non-detectable for both βI-and βII-tryptase over the investigated pH-range. In the 
presence of heparin however, enzymatic activity was readily detected in both βI-
and βII-tryptase, with optimal activity of βI-tryptase incubated with heparin in low 
pH (5.5-6.0) and a marked decline in activity when reaching neutral pH. This in 
contrast to βII-tryptase which showed only a moderate pH-dependence (Fig. 2). 
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Fig. 2 Enzyme activity of βI-tryptase and βII-tryptase incubated with heparin at pH 5.5-7.5. 
 
 
These results indicate that human βI-and βII-tryptase interact with heparin to 
become active and that βI-tryptase reaches optimal activity when this interaction 
occurs at acidic pH, whereas βII-tryptase appears to be less pH-dependent. To 
further investigate this hypothesis of pH-dependence βI-and βII-tryptase were 
analyzed by affinity chromatography on a heparin-Sepharose column equilibrated 
with PBS pH 6.0 or 7.5. The tryptase was eluted from the column step-wise with 
NaCl in increasing concentrations (0.15M-2M). Both βI-and βII-tryptase bound 
strongly to the column at pH 6.0 where approximately 1M NaCl was required for 
elution, a result indicating high affinity for heparin. At pH 7.5 it appears that both 
βI-and βII-tryptase have a considerably lower affinity for heparin since the major 
portion of the sample protein eluted at 0.5M NaCl or less (Fig. 3). 
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Fig. 3 Affinity chromatography of βI-tryptase (A) and βII-tryptase (B) on heparin-Sepharose at pH 
6.0 or 7.5. 
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Dose response experiments where βI-and βII-tryptase were incubated with 
different concentrations of heparin (0.007-7000 µg/ml) showed enzyme activity 
optimums at ~7 µg/ml of heparin for both βI-and βII-tryptase. βI-tryptase 
generally showed substantially higher activity levels than βII-tryptase. At heparin 
concentrations above 7 µg/ml enzyme activity levels decreased for both  βI-and 
βII-tryptase. At the highest concentrations of heparin in the experiment enzyme 
activity levels approached those obtained in absence of heparin. βI-and βII-
tryptase show a bell-shaped dose response curve (Fig. 4). 
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Fig. 4 Dose response for heparin dependent activation of βI-tryptase and βII-tryptase. 
 
 
Discussion 
 
Tryptase is one of the main inflammatory mediators released by mast cell 
degranulation. Tryptase is stored with heparin proteoglycan in its active form in 
the granules. It has previously been shown that recombinant human β-tryptase, 
expressed in insect cells, required heparin to become active (Huang et al 2001). In 
this study recombinant human β-tryptase was expressed in a human cell line, 293-
EBNA cells, to ensure correct folding and glycosylation of the tryptase. We have 
shown in this study that both βI-tryptase and βII-tryptase are dependent on heparin 
to exhibit enzymatic activity. In a parallel study it was shown that heparin was 
also needed for tetramerization of β-tryptase (Hallgren et al 2004).  
We show that the activation of both βI-tryptase and βII-tryptase is strongly 
dependent on heparin and we also demonstrate that the heparin-induced activation 
shows a pH-dependence with activation being optimal at slightly acidic pH (5.5-
6.0). However, human β-tryptase was also activated at neutral pH which differs 
from the results from a previous study on mMCP-6 showing barely detectable 
activity at neutral pH (Hallgren et al 2000).  Human βII-tryptase showed a lower 
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pH-dependence for activation than βI-tryptase and the reason for this is not clear. 
The structural difference between βI-tryptase  and βII-tryptase is at amino acid 
102 where βI-tryptase has a glycosylation site (Asn102) and βII-tryptase instead 
has a Lys residue and is not glycosylated at that site. The difference in function 
between the isoenzymes is therefore suggested to be related to the difference in 
glycosylation, possibly that the oligosaccharide on βI-tryptase facilitates binding 
to heparin. However both βI-tryptase and  βII-tryptase show approximately 
similar affinity for heparin in the experiment using heparin-Sepharose for affinity 
chromatography leading to the hypothesis that the oligosaccharide on βI-tryptase 
is important for assembly of active tetramers without affecting affinity for 
heparin. The parallel study on the subject indeed revealed that βI-tryptase 
primarily formed active tetramers in presence of heparin while βII-tryptase in the 
presence of heparin predominantly formed inactive complexes of larger size than 
tetramer (Hallgren et al 2004), something that could account for the generally 
lower activity level of βII-tryptase. 
The activation mechanism for human β-tryptase is similar to that suggested for 
mMCP-6 (Hallgren et al 2001) with tryptase monomers binding heparin 
proteoglycan in dimers and then assembling dimers into tetramers. Activation of 
human β-tryptase by heparin show a bell shaped dose response curve, an 
indication of tri-molecular interaction and therefore compatible with tryptase 
monomers being cross linked by heparin. The parallel study also showed that β-
tryptase appear to have the same requirements regarding the size of heparin 
oligosaccharide required for binding monomers as mMCP-6 does and that β-
tryptase also can occur as active monomers given the appropriate conditions 
(Hallgren et al 2004).   
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